Funding for this research was provided by:
Bristol-Myers Squibb Foundation (.)
Received: 9 May 2020
Accepted: 19 August 2020
First Online: 7 September 2020
Ethics approval and consent to participate
: Ethics approval was obtained from the Human Research Ethics Committee of the University of Cape Town (ref: 004/2016), the Research Ethics Committee of the University of the Witwatersrand (ref: M160510) and the Western Cape (ref: WC_2016RP19_818) and KwaZulu-Natal (ref: KZN_2016RP59_986) Provincial Department of Health Ethics Committees. All participants provided written informed consent.
: Not applicable.
: AS: is a faculty member of the Bristol-Myers Squibb Foundation and has received an honorarium from Gilead Pharmaceuticals to present hepatitis prevalence data at a South African conference for HIV clinicians.KY: No competing interests.AV: No competing interests.CWS: No competing interests.MS: No competing interests.NPS: No competing interests.AJP: No competing interests.HH: No competing interests.